EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone

Abdulrahman Hummadi iD, Saeed Yafei iD, Dhayf Alrahman Mutawwam, Raed Abutaleb iD, Yahia Solan iD, Abdullah Khawaji, Ali Jaber Alhagawy iD, Turki Algohani, Mamdouh Khardali, Mohammed Hakami iD, Abdulrraheem Daghriri, Wegdan Hezam und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252212060 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Abdulrahman Hummadi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Adult Endocrinology and Diabetes, Jazan Endocrinology & Diabetes Center, Ministry of Health, Jazan 82723, Saudi Arabia. Hauptthemen laut MEDLINE: Pioglitazone, Lipodystrophy, Familial Partial, PPAR gamma, Computational Biology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Familial partial lipodystrophies (FPLDs) are very rare inherited disorders characterized by partial loss of adipose tissue from the upper and lower extremities. At least seven subtypes of FPLD have been identified and are mostly dominantly inherited. FPLD type 3 is caused by mutations in the PPARγ gene, which encodes for the protein peroxisome proliferator-activated receptor gamma (PPARγ). We identified a Saudi female with PFLD3 presented with partial lipoatrophy, uncontrolled diabetes, severe hypertriglyceridemia, and recurrent pancreatitis. The clinical and biochemical findings in this proband were described before and after treatment with Pioglitazone in addition to the conventional treatment. DNA extraction and whole exome sequencing (WES) were performed to detect the variant. The mutant gene was subjected to Sanger analysis to confirm the results. We applied five specific computational prediction tools to assess the pathogenicity of variation, namely the MT, DANN, CADD, BayesDel, and fitCons tools. We assessed protein modeling and stability with the AlphaFold-generated structures for both wild-type and mutant proteins. Finally, we conducted molecular docking using the AutoDock Vina virtual docking. Upon whole exome sequencing, a c.1024C>T p.(Gln342Ter) missense mutation was detected in the PPARγ gene associated with FPLD3. This variant is a novel mutation that has not been described in all genome databases. Sanger analysis confirmed the heterogenicity and pathogenicity of this variant. All five computational prediction tools indicate that this variant is considered highly pathogenic. Our patient showed a dramatic response to Pioglitazone, a synthetic PPARγ agonist. From structural modeling, we found that the enhanced binding affinity of the mutant PPARγ protein to Pioglitazone likely improves the activation of PPARγ, enhancing its transcriptional activity and resulting in better clinical outcomes. These findings extend the spectrum of PPARγ mutations responsible for FPLD3 and highlight the potential for personalized treatment strategies based on genetic mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PioglitazoneLipodystrophy, Familial PartialPPAR gammaComputational BiologyHumansFemaleAdultMolecular Docking SimulationExome SequencingMutationPedigreeMutation, MissenseGenomicsHypoglycemic Agents

Stichwörter der Autor:innen

FPLDPPARγPioglitazonefamilial partial lipodystrophylipodystrophy

Substanzen

PioglitazonePPAR gammaHypoglycemic Agents

Autor:innen und Institutionen

  • Adult Endocrinology and Diabetes, Jazan Endocrinology & Diabetes Center, Ministry of Health, Jazan 82723, Saudi Arabia.
  • Endocrinology Department, Faculty of Medicine and Health Sciences, Taiz University, Taiz 11712, Yemen.
  • Molecular Genetics Department, Jazan Health Affairs, Ministry of Health, Jazan 82617, Saudi Arabia.
  • Pharmacology Department, Jazan Endocrinology & Diabetes Center, Ministry of Health, Jazan 82723, Saudi Arabia.
  • Altewal Hospital, Ministry of Health, Jazan 82723, Saudi Arabia.

ORCID-Profile: Abdulrahman Hummadi, Saeed Yafei, Raed Abutaleb, Yahia Solan, Ali Jaber Alhagawy, Mohammed Hakami

Zitieren

APA

Hummadi, A., Yafei, S., Mutawwam, D. A., Abutaleb, R., Solan, Y., Khawaji, A., Alhagawy, A. J., Algohani, T., Khardali, M., Hakami, M., Daghriri, A., Hezam, W., & Kariri, N. (2024). Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212060

Vancouver

Hummadi A, Yafei S, Mutawwam DA, Abutaleb R, Solan Y, Khawaji A, et al. Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212060

BibTeX
@article{Hummadi2024,
  author = {Hummadi, Abdulrahman and Yafei, Saeed and Mutawwam, Dhayf Alrahman and Abutaleb, Raed and Solan, Yahia and Khawaji, Abdullah and Alhagawy, Ali Jaber and Algohani, Turki and Khardali, Mamdouh and Hakami, Mohammed and Daghriri, Abdulrraheem and Hezam, Wegdan and Kariri, Nourah},
  title = {Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252212060}
}
Kostenlos starten →